Search Results - "ANGENENDT, Philipp"

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686) by Karlovich, Chris, Goldman, Jonathan W, Sun, Jong-Mu, Mann, Elaina, Sequist, Lecia V, Konopa, Krzysztof, Wen, Wei, Angenendt, Philipp, Horn, Leora, Spigel, David, Soria, Jean-Charles, Solomon, Benjamin, Camidge, D Ross, Gadgeel, Shirish, Paweletz, Cloud, Wu, Lin, Chien, Sean, O'Donnell, Patrick, Matheny, Shannon, Despain, Darrin, Rolfe, Lindsey, Raponi, Mitch, Allen, Andrew R, Park, Keunchil, Wakelee, Heather

“…The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated the detection of EGFR…”
Get full text

Integrated Genomic Analysis of Human Glioblastoma Multiforme by Parsons, D. Williams, Jones, Siân, Zhang, Xiaosong, Lin, Jimmy Cheng-Ho, Leary, Rebecca J, Angenendt, Philipp, Mankoo, Parminder, Carter, Hannah, Siu, I. Mei, Gallia, Gary L, Olivi, Alessandro, McLendon, Roger, Rasheed, B. Ahmed, Keir, Stephen, Nikolskaya, Tatiana, Nikolsky, Yuri, Busam, Dana A, Tekleab, Hanna, Diaz, Luis A. Jr, Hartigan, James, Smith, Doug R, Strausberg, Robert L, Marie, Suely Kazue Nagahashi, Shinjo, Sueli Mieko Oba, Yan, Hai, Riggins, Gregory J, Bigner, Darell D, Karchin, Rachel, Papadopoulos, Nick, Parmigiani, Giovanni, Vogelstein, Bert, Velculescu, Victor E, Kinzler, Kenneth W

“…Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein…”
Get full text

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood by HIGGINS, Michaela J, JELOVAC, Danijela, EMENS, Leisha, RILEY, Carol, STEARNS, Vered, DIEHL, Frank, ANGENENDT, Philipp, PENG HUANG, COPE, Leslie, ARGANI, Pedram, MURPHY, Kathleen M, BACHMAN, Kurtis E, BARNATHAN, Evan, GRESHOCK, Joel, WOLFF, Antonio C, PARK, Ben H, BLAIR, Brian, SLATER, Shannon, POWERS, Penny, ZORZI, Jane, JETER, Stacie C, OLIVER, George R, FETTING, John

“…We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer…”
Get full text

Toward optimized antibody microarrays: a comparison of current microarray support materials by Angenendt, Philipp, Glökler, Jörn, Murphy, Derek, Lehrach, Hans, Cahill, Dolores J

“…With the advent of protein and antibody microarray technology several different coatings and protocols have been published, which may be broadly divided into…”
Get full text

Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis by HOLDHOFF, Matthias, SCHMIDT, Kerstin, CHOTI, Michael A, DIAZ, Luis A, DIEHL, Frank, AGGRAWAL, Nishant, ANGENENDT, Philipp, ROMANS, Katharine, EDELSTEIN, Daniel L, TORBENSON, Michael, KINZLER, Kenneth W, VOGELSTEIN, Bert

“…Defining an adequate resection margin of colorectal cancer liver metastases is essential for optimizing surgical technique. We have attempted to evaluate the…”
Get full text

Generation of High Density Protein Microarrays by Cell-free in Situ Expression of Unpurified PCR Products by Angenendt, Philipp, Kreutzberger, Jürgen, Glökler, Jörn, Hoheisel, Jörg D.

“…Due to the success of DNA microarrays and the growing numbers of available protein expression clones, protein microarrays have become more and more popular for…”
Get full text

Microarray technology as a universal tool for high-throughput analysis of biological systems by Sobek, Jens, Bartscherer, Kerstin, Jacob, Anette, Hoheisel, Jvrg D, Angenendt, Philipp

“…Over the last years microarray technology has become one of the principal platform technologies for the high-throughput analysis of biological systems…”
Get more information

Cell-Free Protein Expression and Functional Assay in Nanowell Chip Format by Angenendt, Philipp, Nyarsik, Lajos, Szaflarski, Witold, Glökler, Jörn, Nierhaus, Knud H, Lehrach, Hans, Cahill, Dolores J, Lueking, Angelika

“…The expression and characterization of large protein libraries requires high-throughput tools for rapid and cost-effective expression and screening. A…”
Get full text

Progress in protein and antibody microarray technology by Angenendt, Philipp

“…Protein and antibody microarray technologies are two of the most propitious technologies for the screening of complex protein samples. Nevertheless, to…”
Get full text

Bacterial protein microarrays for identification of new potential diagnostic markers forNeisseria meningitidis infections by Steller, Sigrid, Angenendt, Philipp, Cahill, Dolores J., Heuberger, Sigrid, Lehrach, Hans, Kreutzberger, Jürgen

Get full text

Next generation of protein microarray support materials by Angenendt, Philipp, Glökler, Jörn, Sobek, Jens, Lehrach, Hans, Cahill, Dolores J.

Get full text

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells by Yun, Jihye, Rago, Carlo, Cheong, Ian, Pagliarini, Ray, Angenendt, Philipp, Rajagopalan, Harith, Schmidt, Kerstin, Willson, James K.V, Markowitz, Sandy, Zhou, Shibin, Diaz, Luis A. Jr, Velculescu, Victor E, Lengauer, Christoph, Kinzler, Kenneth W, Vogelstein, Bert, Papadopoulos, Nickolas

“…Tumor progression is driven by genetic mutations, but little is known about the environmental conditions that select for these mutations. Studying the…”
Get full text

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses by Jones, Siân, Zhang, Xiaosong, Parsons, D. Williams, Lin, Jimmy Cheng-Ho, Leary, Rebecca J, Angenendt, Philipp, Mankoo, Parminder, Carter, Hannah, Kamiyama, Hirohiko, Jimeno, Antonio, Hong, Seung-Mo, Fu, Baojin, Lin, Ming-Tseh, Calhoun, Eric S, Kamiyama, Mihoko, Walter, Kimberly, Nikolskaya, Tatiana, Nikolsky, Yuri, Hartigan, James, Smith, Douglas R, Hidalgo, Manuel, Leach, Steven D, Klein, Alison P, Jaffee, Elizabeth M, Goggins, Michael, Maitra, Anirban, Iacobuzio-Donahue, Christine, Eshleman, James R, Kern, Scott E, Hruban, Ralph H, Karchin, Rachel, Papadopoulos, Nickolas, Parmigiani, Giovanni, Vogelstein, Bert, Velculescu, Victor E, Kinzler, Kenneth W

“…There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently…”
Get full text

Protein and antibody microarray technology by Glökler, Jörn, Angenendt, Philipp

“…Following the age of genomics having sequenced the human genome, interest is shifted towards the function of genes. This new age of proteomics brings about a…”
Get full text

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M, Fu, Siqing, Naing, Aung, Falchook, Gerald S, Hong, David S, Holley, Veronica R, Cabrilo, Goran, Wheler, Jennifer J, Piha-Paul, Sarina A, Zinner, Ralph G, Bedikian, Agop Y, Overman, Michael J, Kee, Bryan K, Kim, Kevin B, Kopetz, E Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle

“…Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157…”
Get full text

Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS by Fredebohm, Johannes, Mehnert, Daniel H, Löber, Ann-Kathrin, Holtrup, Frank, van Rahden, Vanessa, Angenendt, Philipp, Diehl, Frank

“…We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay…”
Get more information

Next generation of protein microarray support materials:: Evaluation for protein and antibody microarray applications by Angenendt, Philipp, Glökler, Jörn, Sobek, Jens, Lehrach, Hans, Cahill, Dolores J.

“…The performance of protein and antibody microarrays is dependent on various factors, one of which is the use of an appropriate microarray surface for the…”
Get full text

Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib by Krissel, Heiko, Hennig, Andrea, Zhang, Danny, Ito, Rodrigo, Gonschorek, Christine, Souza, Fabricio, Poethig, Martina, Schostack, Kathleen, Reischl, Joachim, Angenendt, Philipp, Childs, Barrett H., Teufel, Michael

“…Abstract Background: In a retrospective analysis performed in a phase II study evaluating efficacy and safety of the MEK-inhibitor refametinib plus sorafenib…”
Get full text

Evaluation of antibodies and microarray coatings as a prerequisite for the generation of optimized antibody microarrays by Angenendt, Philipp, Glökler, Jörn

“…Antibody microarrays are becoming a major tool for the parallel analysis of complex samples. So far, many efforts have been made to increase the complexity and…”
Get more information

Abstract 927: Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686) by Goldman, Jonathan W., Karlovich, Chris, Mann, Elaina, Rolfe, Lindsey, Matheny, Shannon, Despain, Darrin, Angenendt, Philipp, Stamm, Claudia, Wakelee, Heather A., Soria, Jean-Charles, Solomon, Benjamin, Camidge, D. R., Dziadziuszko, Rafal, Horn, Leora, Gadgeel, Shirish, Raponi, Mitch, Allen, Andrew R., Sequist, Lecia V.

“…Abstract Background: EGFR mutation testing is required to identify patients who may respond to TKI therapy. However, tumor biopsies from NSCLC patients can…”
Get full text